Prolyl oligopeptidase induces angiogenesis both in vitro and in vivo in a novel regulatory manner

British Journal of Pharmacology

Volumn 163, Issue 8, 2011, Pages 1666-1678

  Myohanen T T ^a   Tenorio Laranga, J ^a   Jokinen, B ^a   Vazquez Sanchez R ^a   Moreno Baylach, M J ^a   Garcia Horsman J A ^a   Mannisto P T ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Ac SDKP; prolyl oligopeptidase inhibitor; serine protease; thymosin 4; tumour angiogenesis

Indexed keywords

4 PHENYL BUTANOYL PROLYL 2 CYANOPYRROLIDINE; ACETYL N SERYLASPARAGINYLLYSYLPROLINE; CD31 ANTIGEN; KYP 2047; LISINOPRIL; MATRIGEL; PROLYL ENDOPEPTIDASE; PROLYL ENDOPEPTIDASE INHIBITOR; SOMATOSTATIN; TETRAPEPTIDE; THYMOSIN BETA4; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME IMMUNOASSAY; ENZYME RELEASE; ENZYME SYNTHESIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HYDROLYSIS; IN VITRO STUDY; IN VIVO STUDY; KIDNEY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; PROTEIN LOCALIZATION; PROTEIN PROCESSING; RAT;

ANGIOGENESIS INHIBITORS; ANIMALS; BIOCOMPATIBLE MATERIALS; COLLAGEN; DRUG COMBINATIONS; ENDOTHELIAL CELLS; GROWTH INHIBITORS; HUMANS; KIDNEY; LAMININ; MALE; NEOVASCULARIZATION, PATHOLOGIC; OLIGOPEPTIDES; PROLINE; PROTEOGLYCANS; RATS; RATS, INBRED WF; SERINE ENDOPEPTIDASES; SERINE PROTEINASE INHIBITORS; THYMOSIN; UMBILICAL VEINS;

EID: 79960905130     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2010.01146.x     Document Type: Article

References (58)

1. Alexander SPH, Mathie A, Peters JA, (2009). Guide to Receptors and Channels (GRAC), 4th edition. Br J Pharmacol 158 (Suppl. 1): S1-S254.
2. Bogden AE, Carde P, de Paillette ED, Moreau JP, Tubiana M, Frindel E, (1991). Amelioration of chemotherapy-induced toxicity by cotreatment with AcSDKP, a tetrapeptide inhibitor of hematopoietic stem cell proliferation. Ann N Y Acad Sci 628: 126-139.
3. Bonnet D, Lemoine FM, Khoury E, Pradelles P, Najman A, Guigon M, (1992). Reversible inhibitory effects and absence of toxicity of the tetrapeptide acetyl-N-Ser-Asp-Lys-Pro (AcSDKP) in human long-term bone marrow culture. Exp Hematol 20: 1165-1169.
4. Bradford MM, (1976). A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254.
5. Brandt I, Scharpe S, Lambeir AM, (2007). Suggested functions for prolyl oligopeptidase: a puzzling paradox. Clin Chim Acta 377: 50-61. (Pubitemid 44914066)
6. Brandt I, Gerard M, Sergeant K, Devreese B, Baekelandt V, Augustyns K, et al,. (2008). Prolyl oligopeptidase stimulates the aggregation of alpha-synuclein. Peptides 29: 1472-1478.
7. Carmeliet P, Jain RK, (2000). Angiogenesis in cancer and other diseases. Nature 407: 249-257.
8. Cashman JD, Eaves AC, Eaves CJ, (1994). The tetrapeptide AcSDKP specifically blocks the cycling of primitive normal but not leukemic progenitors in long-term culture: evidence for an indirect mechanism. Blood 84: 1534-1542. (Pubitemid 24273022)
9. Cavasin MA, (2006). Therapeutic potential of thymosin-beta4 and its derivative N-acetyl-seryl-aspartyl-lysyl-proline (Ac-SDKP) in cardiac healing after infarction. Am J Cardiovasc Drugs 6: 305-311. (Pubitemid 44749340)
10. Cavasin MA, Rhaleb NE, Yang XP, Carretero OA, (2004). Prolyl oligopeptidase is involved in release of the antifibrotic peptide Ac-SDKP. Hypertension 43: 1140-1145. (Pubitemid 38579927)
11. Cavasin MA, Liao TD, Yang XP, Yang JJ, Carretero OA, (2007). Decreased endogenous levels of Ac-SDKP promote organ fibrosis. Hypertension 50: 130-136. (Pubitemid 46986021)
12. Comte L, Lorgeot V, Volkov L, Roullet B, Tubiana N, Praloran V, (1997). AcSDKP plasma concentrations in patients with solid tumours: comparison of two chemotherapeutic regimens. Cancer Lett 112: 1-4. (Pubitemid 27067420)
13. Di Daniel E, Glover CP, Grot E, Chan MK, Sanderson TH, White JH, et al,. (2009). Prolyl oligopeptidase binds to GAP-43 and functions without its peptidase activity. Mol Cell Neurosci 41: 373-382.
14. Folkman J, (1971). Tumor angiogenesis: therapeutic implications. N Engl J Med 285: 1182-1186.
15. Furuya M, Yonemitsu Y, Aoki I, (2009). III. Angiogenesis: complexity of tumor vasculature and microenvironment. Curr Pharm Des 15: 1854-1867.
16. Gaggar A, Jackson PL, Noerager BD, O'Reilly PJ, McQuaid DB, Rowe SM, et al,. (2008). A novel proteolytic cascade generates an extracellular matrix-derived chemoattractant in chronic neutrophilic inflammation. J Immunol 180: 5662-5669.
17. Garcia-Horsman JA, Männistö PT, Venäläinen JI, (2007). On the role of prolyl oligopeptidase in health and disease. Neuropeptides 41: 1-24. (Pubitemid 46091700)
18. Goossens F, De Meester I, Vanhoof G, Scharpe S, (1996). Distribution of prolyl oligopeptidase in human peripheral tissues and body fluids. Eur J Clin Chem Clin Biochem 34: 17-22. (Pubitemid 26053038)
19. Hannappel E, (2010). Thymosin beta4 and its posttranslational modifications. Ann N Y Acad Sci 1194: 27-35.
20. He MF, Huang YH, Wu LW, Ge W, Shaw PC, But PP, (2009). Triptolide functions as a potent angiogenesis inhibitor. Int J Cancer 126: 266-278.
21. Ishino T, Ohtsuki S, Homma K, Natori S, (1998). cDNA cloning of mouse prolyl endopeptidase and its involvement in DNA synthesis by Swiss 3T3 cells. J Biochem (Tokyo) 123: 540-545. (Pubitemid 28143512)
22. Jalkanen AJ, Puttonen KA, Venäläinen JI, Sinervä V, Mannila A, Ruotsalainen S, et al,. (2007). Beneficial effect of prolyl oligopeptidase inhibition on spatial memory in young but not in old scopolamine-treated rats. Basic Clin Pharmacol Toxicol 100: 132-138. (Pubitemid 46146718)
23. Jarho EM, Venalainen JI, Huuskonen J, Christiaans JA, Garcia-Horsman JA, Forsberg MM, et al,. (2004). A cyclopent-2-enecarbonyl group mimics proline at the P2 position of prolyl oligopeptidase inhibitors. J Med Chem 47: 5605-5607. (Pubitemid 39447255)
24. Kusinski M, Wdzieczak-Bakala J, Liu JM, Bignon J, Kuzdak K, (2006). AcSDKP: a new potential marker of malignancy of the thyroid gland. Langenbecks Arch Surg 391: 9-12. (Pubitemid 43188594)
25. Larrinaga G, Perez I, Blanco L, Lopez JI, Andres L, Etxezarraga C, et al,. (2010). Increased prolyl endopeptidase activity in human neoplasia. Regul Pept 163: 102-106.
26. Lenfant M, Grillon C, Rieger KJ, Sotty D, Wdzieczak-Bakala J, (1991). Formation of acetyl-Ser-Asp-Lys-Pro, a new regulator of the hematopoietic system, through enzymatic processing of thymosin beta 4. Ann N Y Acad Sci 628: 115-125.
27. Liozon E, Volkov L, Comte L, Trimoreau F, Pradelles P, Bordessoule D, et al,. (1995). AcSDKP serum concentrations vary during chemotherapy in patients with acute myeloid leukaemia. Br J Haematol 89: 917-920.
28. Liu JM, Lawrence F, Kovacevic M, Bignon J, Papadimitriou E, Lallemand JY, et al,. (2003). The tetrapeptide AcSDKP, an inhibitor of primitive hematopoietic cell proliferation, induces angiogenesis in vitro and in vivo. Blood 101: 3014-3020. (Pubitemid 36857989)
29. Liu JM, Bignon J, Ilic V, Briscoe C, Lallemand JY, Riches A, et al,. (2006). Evidence for an association of high levels of endogenous Acetyl-Ser-Asp-Lys-Pro, a potent mediator of angiogenesis, with acute myeloid leukemia development. Leuk Lymphoma 47: 1915-1920. (Pubitemid 44649778)
30. Liu JM, Kusinski M, Ilic V, Bignon J, Hajem N, Komorowski J, et al,. (2008). Overexpression of the angiogenic tetrapeptide AcSDKP in human malignant tumors. Anticancer Res 28: 2813-2817.
31. Malinda KM, Goldstein AL, Kleinman HK, (1997). Thymosin beta 4 stimulates directional migration of human umbilical vein endothelial cells. FASEB J 11: 474-481. (Pubitemid 27259989)
32. Malinda KM, Sidhu GS, Mani H, Banaudha K, Maheshwari RK, Goldstein AL, et al,. (1999). Thymosin beta4 accelerates wound healing. J Invest Dermatol 113: 364-368. (Pubitemid 29449075)
33. Männistö PT, Venäläinen JI, Jalkanen AJ, Garcia-Horsman JA, (2007). Prolyl oligopeptidase: a potential target for the treatment of cognitive disorders. Drugs News Persp 20: 293-305. (Pubitemid 47345221)
34. Monpezat JP, Frindel E, (1989). Further studies on the biological activities of the CFU-S inhibitory tetrapeptide AcSDKP. I. The precise point of the cell cycle sensitive to AcSDKP. Studies on the effect of AcSDKP on GM-CFC and on the possible involvement of T-lymphocytes in AcSDKP response. Exp Hematol 17: 1077-1080. (Pubitemid 20019300)
35. Moreno-Baylach MJ, Felipo V, Männistö PT, Garcia-Horsman JA, (2008). Expression and traffic of cellular prolyl oligopeptidase are regulated during cerebellar granule cell differentiation, maturation, and aging. Neuroscience 156: 580-585.
36. Myöhänen TT, Venäläinen JI, Garcia-Horsman JA, Piltonen M, Männistö PT, (2008a). Cellular and subcellular distribution of rat brain prolyl oligopeptidase and its association with specific neuronal neurotransmitters. J Comp Neurol 507: 1694-1708. (Pubitemid 351468218)
37. Myöhänen TT, Venäläinen JI, Garcia-Horsman JA, Piltonen M, Männistö PT, (2008b). Distribution of prolyl oligopeptidase in the mouse whole-body sections and peripheral tissues. Histochem Cell Biol 130: 993-1003.
38. Myöhänen TT, Garcia-Horsman JA, Tenorio-Laranga J, Männistö PT, (2009a). Issues about the physiological functions of prolyl oligopeptidase based on its discordant spatial association with substrates and inconsistencies among mRNA, protein levels, and enzymatic activity. J Histochem Cytochem 57: 831-848.
39. Myöhänen TT, Kääriäinen TM, Jalkanen AJ, Piltonen M, Männistö PT, (2009b). Localization of prolyl oligopeptidase in the thalamic and cortical projection neurons: A retrograde neurotracing study in the rat brain. Neurosci Lett 450: 201-205.
40. Ohtsuki S, Homma K, Kurata S, Komano H, Natori S, (1994). A prolyl endopeptidase of Sarcophaga peregrina (flesh fly): its purification and suggestion for its participation in the differentiation of the imaginal discs. J Biochem (Tokyo) 115: 449-453. (Pubitemid 24096455)
41. Ohtsuki S, Homma K, Kurata S, Natori S, (1997). Nuclear localization and involvement in DNA synthesis of Sarcophaga prolyl endopeptidase. J Biochem (Tokyo) 121: 1176-1181. (Pubitemid 27290536)
42. Peng H, Carretero OA, Raij L, Yang F, Kapke A, Rhaleb NE, (2001). Antifibrotic effects of N-acetyl-seryl-aspartyl-Lysyl-proline on the heart and kidney in aldosterone-salt hypertensive rats. Hypertension 37 (Part 2): 794-800. (Pubitemid 32199068)
43. Polgar L, (1994). Prolyl oligopeptidases. Methods Enzymol 244: 188-200.
44. Rawlings ND, Barrett AJ, (1994). Families of serine peptidases. Methods Enzymol 244: 19-61.
45. Rawlings ND, Barrett AJ, Bateman A, (2010). MEROPS: the peptidase database. Nucleic Acids Res 38 (Database issue): D227-D233.
46. Rossdeutsch A, Smart N, Riley PR, (2008). Thymosin beta4 and Ac-SDKP: tools to mend a broken heart. J Mol Med 86: 29-35.
47. Roy R, Yang J, Moses MA, (2009). Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer. J Clin Oncol 27: 5287-5297.
48. Schulz I, Zeitschel U, Rudolph T, Ruiz-Carrillo D, Rahfeld JU, Gerhartz B, et al,. (2005). Subcellular localization suggests novel functions for prolyl endopeptidase in protein secretion. J Neurochem 94: 970-979. (Pubitemid 41170585)
49. Shojaei F, Wu X, Zhong C, Yu L, Liang XH, Yao J, et al,. (2007). Bv8 regulates myeloid-cell-dependent tumour angiogenesis. Nature 450: 825-831. (Pubitemid 350231321)
50. Smart N, Risebro CA, Melville AA, Moses K, Schwartz RJ, Chien KR, et al,. (2007a). Thymosin beta4 induces adult epicardial progenitor mobilization and neovascularization. Nature 445: 177-182. (Pubitemid 46095717)
51. Smart N, Rossdeutsch A, Riley PR, (2007b). Thymosin beta4 and angiogenesis: modes of action and therapeutic potential. Angiogenesis 10: 229-241. (Pubitemid 350045880)
52. Sun HQ, Yin HL, (2007). The beta-thymosin enigma. Ann N Y Acad Sci 1112: 45-55.
53. Tenorio-Laranga J, Valero ML, Männistö PT, Sanchez del Pino M, Garcia-Horsman JA, (2009). Combination of snap freezing, differential pH two-dimensional reverse-phase high-performance liquid chromatography, and iTRAQ technology for the peptidomic analysis of the effect of prolyl oligopeptidase inhibition in the rat brain. Anal Biochem 393: 80-87.
54. Tenorio-Laranga J, Coret-Ferrer F, Casanova-Estruch B, Burgal M, Garcia-Horsman JA, (2010). Prolyl oligopeptidase is inhibited in relapsing-remitting multiple sclerosis. J Neuroinflammation 7: 23.
55. Venäläinen JI, Garcia-Horsman JA, Forsberg MM, Jalkanen A, Wallen EA, Jarho EM, et al,. (2006). Binding kinetics and duration of in vivo action of novel prolyl oligopeptidase inhibitors. Biochem Pharmacol 71: 683-692. (Pubitemid 43122001)
56. Wake H, Mori S, Liu K, Takahashi HK, Nishibori M, (2009). Histidine-rich glycoprotein inhibited high mobility group box 1 in complex with heparin-induced angiogenesis in matrigel plug assay. Eur J Pharmacol 623: 89-95.
57. Wang D, Carretero OA, Yang XY, Rhaleb NE, Liu YH, Liao TD, et al,. (2004). N-acetyl-seryl-aspartyl-lysyl-proline stimulates angiogenesis in vitro and in vivo. Am J Physiol Heart Circ Physiol 287: H2099-H2105. (Pubitemid 39430749)
58. Williams RS, Cheng L, Mudge AW, Harwood AJ, (2002). A common mechanism of action for three mood-stabilizing drugs. Nature 417: 292-295. (Pubitemid 34534711)